Latest:
Contralateral Breast Cancer Treatment With Germline Mutation Carriers
Siddartha Yadav, MD, FACP, of Mayo Clinic, discusses personalizing treatment for patients with germline–mutant contralateral breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Mark Leick, MD
Latest:
Dr Leick on Limitations Associated With CAR T-Cell Therapy in Hematologic Malignancies
Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.
Anirban P. Mitra, MD, PhD
Latest:
Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBC
Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.
Cristiane Bergerot PhD, MS, BS
Latest:
Dr. Bergerot on Improved HRQoL With a Higher Starting Dose of Lenvatinib Plus Everolimus in RCC
Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.
Vanderbilt-Ingram Cancer Center
Latest:
VIGH, VICC Establish Cancer Research Program in Zambia
Vanderbilt University Medical Center and the University of Zambia are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia and to encourage U.S.-based researchers to engage in cancer research in low- and middle-income countries.
Annie Deck-Miller
Latest:
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.
Vikas Mehta, MD, MPH, FACS
Latest:
BRONx-CAN Program Aims to Deliver the Best Cancer Treatments Early
Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.